SecBot SecBot
Biotech Drug Report Generated Aug 20, 2026

RGX-111

RGNX·REGENXBIO Inc.
BEARISH
Drug Impact Rating2/10
Trial Phase
Phase I/II (on FDA clinical hold since January 2026)
Time to Market
Unknown — far off at best. The program is on clinical hold in Phase I/II; even if the hold is lifted, a potential approval is likely several years away, and the hold could end the program.
Why 2/10
No hard, dated catalyst is scheduled for RGX-111 within the next ~12 months: it is a Phase I/II program under an FDA clinical hold placed January 2026 (neoplasm case) with no recorded resolution date, and it is a minor program within REGENXBIO, whose value drivers are RGX-202, the wet-AMD programs and RGX-121 — so the drug rates low on both proximity and concentration.
Actionable Insight ▼ BEARISH

For RGNX holders, RGX-111 is not the swing factor — watch for any FDA/company statement on whether the clinical hold is lifted (resolution would be a modest positive, continuation a lingering overhang), but the stock's real binaries are the RGX-202 BLA submission and pivotal wet-AMD topline expected in Q3-Q4 2026. For anyone trading the drug itself: there is no dated catalyst on the calendar, so treat RGX-111 as de-risked-to-negative until the hold status changes.

Price Chart

Loading chart...

Executive Summary

RGX-111 is REGENXBIO Inc.'s (Nasdaq: RGNX) investigational one-time gene therapy for MPS I (Hurler syndrome), and it is in deep trouble: the FDA placed the Phase I/II program on clinical hold in January 2026 after a trial participant developed a neoplasm (tumor), and no resolution of the hold is recorded in SecBot data through the August 2026 Q2 report. It is a minor program inside a larger pipeline — RGNX's near-term value drivers are the RGX-202 Duchenne BLA (Q3 2026), pivotal wet-AMD topline data (Q4 2026) and the RGX-121 BLA resubmission (Q3 2026) — so RGX-111 alone is unlikely to move the stock much.

How It Works

RGX-111 is a one-time gene therapy for Mucopolysaccharidosis Type I (MPS I), specifically the severe Hurler form. The idea is to deliver a working copy of the gene MPS I patients are missing so their own cells can produce the enzyme they lack — a potential single-treatment alternative to lifelong enzyme-replacement infusions for a rare, serious inherited disease.

Trial Status

Per SecBot's SEC-derived catalyst record (high confidence, negative sentiment), the FDA placed a clinical hold on RGX-111 in January 2026 following a case of neoplasm (tumor) in a Phase I/II study participant. The stock fell -5.76% (1-day) and -1.53% (5-day) around the recorded catalyst date. No hold resolution or resumption date appears in local data through the company's August 6, 2026 Q2 report, which still lists RGX-111 among pipeline programs but gives it no headline catalyst.

The Two-Sided Case

▲ Bull Case4
The program is not formally discontinued: RGX-111 still appears among REGENXBIO's pipeline programs in the Q2 2026 earnings 8-K, leaving room for a hold-resolution outcome. (Source: Q2 2026 8-K filing analysis)
Street coverage on the parent company is constructive: analyst consensus as of Aug 2026 was 11 Buy + 6 Strong Buy + 2 Hold, 0 Sell, with a mean price target of $22.80 (median $19.50) versus a ~$10.91 observed price on Aug 12 — roughly 62% implied upside per the analyst snapshot.
Several tracked institutions accumulated RGNX in 2026-Q2 13F filings — Susquehanna doubled (+190.8% shares), D.E. Shaw doubled (+149.2%), Citigroup doubled (+204.2%), Vanguard added (+33%). (Source: bull/bear case institutional-accumulation rows; delayed 13F data)
FINRA short interest declined 16.6% at the 7/31/2026 settlement to ~7.19M shares (~10.9% of estimated shares outstanding, days-to-cover 3.79), down from ~20.2% of estimated shares outstanding at the 6/30/2026 settlement. (Source: FINRA short-position data)
▼ Bear Case5
FDA clinical hold placed January 2026 after a neoplasm (tumor) case in a Phase I/II participant — a serious safety signal that can end a gene-therapy program; no resolution is recorded in local data through August 2026. (Source: SEC-derived catalyst record, sentiment negative, confidence high)
The stock reacted negatively to the hold: -5.76% one-day move on the recorded catalyst date.
Regulatory headwinds across the platform: the sister MPS program RGX-121 received an FDA Complete Response Letter in February 2026 (concerns over study eligibility criteria, external-control comparability, surrogate endpoint validity), with the company appealing and planning resubmission — a reminder that these MPS gene therapies face a tough FDA bar. (Source: SEC-derived catalyst records + Feb 2026 8-K)
Elevated bearish positioning: FINRA short interest was ~10.46M shares (~20.2% of estimated shares outstanding) at the 6/30/2026 settlement, and daily short-volume flow ratios ran 60-71% on several days in May-June 2026 (short-sale execution flow, not outstanding short interest). (Source: FINRA short-interest and short-volume data)
Capital and litigation overhangs: a July 2026 offering raised ~$107.8M net at $9.00/share (analyzed as ~17-20% dilution), the CMO sold shares in June-July 2026 (some under a 10b5-1 plan), and a shareholder-litigation firm publicized a federal securities lawsuit investigation in July 2026. (Source: offering 8-K analysis, Form 4 records, PR Newswire press release)

Upcoming Catalysts

  • FDA decision on lifting/continuing the RGX-111 clinical hold (no date scheduled in sourced data)
  • RGX-202 (Duchenne) BLA submission expected Q3 2026 under accelerated-approval pathway
  • RGX-121 BLA resubmission expected Q3 2026 after positive FDA Type A meeting
  • Topline data from pivotal wet-AMD studies (ATMOSPHERE and ASCENT) expected Q4 2026
  • Q3 2026 earnings report and pipeline updates

Source Filing

The SecBot filing or press-release report that triggered this drug report:

REGENXBIO Inc. Press Release RGNX ·Originating report

Sources · 8

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 sec.gov5 sec.gov6 prnewswire.com7 prnewswire.com8 prnewswire.com